PILL — Canntab Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapSucker Stock
- CA$0.58m
- CA$2.57m
- CA$0.29m
Annual income statement for Canntab Therapeutics, fiscal year end - May 31st, CAD millions except per share, conversion factor applied.
2018 May 31st | 2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.042 | 0.24 | 0.133 | 0 | 0.293 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.069 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.45 | 2.74 | 2.75 | 3.78 | 5.87 |
| Operating Profit | -2.41 | -2.5 | -2.62 | -3.78 | -5.57 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.41 | -2.46 | -2.61 | -4.42 | -3.69 |
| Net Income After Taxes | -2.41 | -2.46 | -2.61 | -4.42 | -3.69 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.41 | -2.46 | -2.61 | -4.42 | -3.69 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.41 | -2.46 | -2.61 | -4.42 | -3.69 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.079 | -0.097 | -0.096 | -0.12 | -0.058 |